These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
588 related items for PubMed ID: 27482643
1. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM. Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643 [Abstract] [Full Text] [Related]
3. Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. Park YJ, Hyun SH, Moon SH, Lee KH, Min BH, Lee JH, Kim WS, Kim SJ, Choi JY. Sci Rep; 2021 Apr 29; 11(1):9243. PubMed ID: 33927319 [Abstract] [Full Text] [Related]
4. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. Albano D, Bertoli M, Ferro P, Fallanca F, Gianolli L, Picchio M, Giubbini R, Bertagna F. Eur J Nucl Med Mol Imaging; 2017 Apr 29; 44(4):589-597. PubMed ID: 27619357 [Abstract] [Full Text] [Related]
9. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Ambrosini V, Rubello D, Castellucci P, Nanni C, Farsad M, Zinzani P, Alavi A, Tehranipour N, Al-Nahhas A, Fanti S. Nucl Med Rev Cent East Eur; 2006 Apr 29; 9(1):37-40. PubMed ID: 16791802 [Abstract] [Full Text] [Related]
11. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. Wei WX, Huang JJ, Li WY, Zhang X, Xia Y, Jiang WQ, Fan W, Li ZM. Chin J Cancer; 2015 Dec 02; 34(12):608-13. PubMed ID: 26630874 [Abstract] [Full Text] [Related]
12. Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study. Hwang JP, Moon JH, Kim HK, Lee MH, Lim CH, Park SB, Yoon JK, Park JM. Medicine (Baltimore); 2021 May 28; 100(21):e26015. PubMed ID: 34032720 [Abstract] [Full Text] [Related]
14. Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin's lymphoma: A study of 328 patients. Alobthani G, Romanov V, Isohashi K, Matsunaga K, Watabe T, Kato H, Tatsumi M, Shimosegawa E, Hatazawa J. Hell J Nucl Med; 2018 May 28; 21(1):7-14. PubMed ID: 29550841 [Abstract] [Full Text] [Related]
16. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab. Lim I, Park JY, Kang HJ, Hwang JP, Lee SS, Kim KM, Choi TH, Yang SH, Kim BI, Choi CW, Lim SM. Acta Haematol; 2013 May 28; 130(2):74-82. PubMed ID: 23548464 [Abstract] [Full Text] [Related]
17. Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection. Kim SH, Song BI, Kim HW, Won KS, Son YG, Ryu SW. Korean J Radiol; 2020 Jul 28; 21(7):829-837. PubMed ID: 32524783 [Abstract] [Full Text] [Related]